Google
Trusted Resources: News & Events
Latest announcements and gatherings
Investigational Oral Inhibitor IMR-687 Shows Promising Results in Ongoing Phase 2 Clinical Trial
Imara’s investigational oral inhibitor IMR-687 is well-tolerated, and shows signs of potential for lowering blood biomarkers of sickle cell anemia (SCA), early data from a Phase 2 trial show. The results were presented at the 24th Congress of the European Hematology Association (EHA), held recently in Amsterdam, the Netherlands.
“We are encouraged by this interim Phase 2a analysis that reinforces our belief in the potential of IMR-687 as a single oral, once-a-day therapeutic,” Rahul D. Ballal, CEO of Imara, said in a press release.
“IMR-687 uniquely targets both red cell and white cell aspects of the disease, and we are working to expeditiously advance this novel therapy through clinical development, with a goal of delivering it to patients with SCD [sickle cell disease] who are in need of innovative treatment options,” Ballal added.
The highly potent therapy is an oral inhibitor of the phosphodiesterase 9 (PDE9) enzyme found in red blood cells. Inhibition of PDE9 in preclinical studies with cells and animal models showed that IMR-687 increases fetal hemoglobin.
+myBinderRelated Content
-
bluebird bio Presents New Data from HGB-205 Study of LentiGlobinTM Drug Product in Patients with Transfusion-Depende...First patient with severe sickle cell di...
-
Global Blood Therapeutics Receives EMA PRIME Designation for GBT440 for the Treatment of Sickle Cell Disease (SCD)GBT440 is First Potential Treatment for ...
-
Gamida Cell to Present Data from NiCord® Programs at the 2018 BMT Tandem MeetingsGamida Cell, a leading cellular and immu...
-
Sickle cell patient with severe anemia rapidly improves with voxelotor, case study showsGlobal Blood Therapeutics (GBT) reported...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
Prevention of Conversion to Abnormal Transcranial Doppler With Hydroxyurea in Sickle Cell Anemia: A Phase III Intern...Children with sickle cell anemia (SCA) a...
-
bluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.